Prevention of Recurrent Superficial Bladder Tumors by Oral Etretinate: Preliminary Results of a Randomized, Double Blind Multicenter Trial in Switzerland

Publisher Website
Google Scholar
Abstract
Retinoids influence the proliferation and differentiation of epithelial tissues. Preliminary results of a double-blind randomized trial in the prevention of recurrent superficial bladder tumors are promising. Patients treated with an oral etertinate tend to have less tumor recurrences and transurethral resections. The number of multifocal recurrences after 12 mo. of treatment is significantly lower (P < 0.02). There also are less dropouts owing to inefficacy of treatment.